The U.S. Food and Drug Administration has approved a new medication for attention deficit hyperactivity disorder, offering patients a treatment option that works differently from existing stimulant and nonstimulant therapies. The drug, designated CTx-001, targets a brain pathway not previously used in ADHD medications, potentially providing relief for the millions of children and adults who do not respond well to current treatments.
Clinical trials showed that CTx-001 reduced core ADHD symptoms such as inattention, hyperactivity and impulsivity by an average of 42 percent compared with placebo over eight weeks. Unlike traditional stimulants that boost dopamine and norepinephrine levels, this drug modulates a glutamate receptor in the prefrontal cortex, the brain region responsible for executive function and self control. Researchers say this mechanism may produce fewer side effects like insomnia, appetite loss and cardiovascular strain that often lead patients to discontinue stimulant therapy.
The approval is based on data from two Phase 3 studies involving more than 1,200 participants ages 6 to 65. In both trials, the drug met primary endpoints for improving ADHD symptoms as measured by standardized rating scales. Common side effects included mild headache and nausea, but no serious adverse events were reported. The drug is expected to be available by prescription in the coming weeks as a once daily tablet.
For patients who have struggled with existing options, this new pathway represents a meaningful step forward. The FDA’s decision comes at a time when ADHD diagnoses continue to rise, and many adults and children face limited choices due to contraindications or poor tolerability. Doctors note that having a medication with a distinct mechanism allows for more personalized treatment plans, especially for those with co occurring conditions such as anxiety or tic disorders.
Ongoing studies are examining the drug’s long term safety and its potential use in younger children. Researchers are also exploring whether the same glutamate targeting approach could help treat other conditions involving attention and impulse control. With this approval, patients and clinicians gain a new tool that may change how ADHD is managed for years to come.